Biotech Values

[ghmm]

IPF:

I have not seen the paper to comment fully still I think one should NOT read too much into this
1-We already know IPF is a progressive disease and neither approved agent halts progression.
2-Its a rather small study in a HIGHLY variable disease
3-Granted its biased but Roche actually has some much larger datasets on treatment benefit continuing out past 1 year.

With those caveats its interesting ITMN's second study (ASCEND) was designed to be 48 weeks because one of the trials in the first studies (CAPACITY) was significance till that point (and ended up failing badly while the other was stat significant).

I am long FGEN and other companies with IPF interest and was an ITMN long for disclosure.